Cancer Pharmacogenomics Development, Science, Translation

More documents

Recommendations

Info

Tamoxifen Biotransformation Jin et al., J. Natl. <strong>Cancer</strong> Inst. 2005; 97:20-39. Reprinted by permission of the Oxford University Press.
CYP2D6 Pharmacogenetics Number of Subjects 120 80 40 1011 Subjects UMs EMs PMs cutoff 0 0.01 0.1 1 10 100 Debrisoquine/4-Hydroxydebrisoquine Metabolic Ratio Reprinted by permission from Macmillan Publishers Ltd. Bertilsson, L. et al. Clin. Pharmacol. Ther. 1992; 51: 388-397. Copyright 1992.
Page 1 and 2: Cancer Pharmacogenomics Development
Page 3 and 4: Pharmacogenetics-Pharmacogenomics C
Page 5 and 6: Pharmacogenetics-Pharmacogenomics S
Page 7 and 8: Pharmacogenetics-Pharmacogenomics F
Page 9 and 10: • Low TPMT TPMT Genetic Polymorph
Page 11: Pharmacogenetics-Pharmacogenomics F
Page 15 and 16: Tamoxifen Pharmacogenetics No Tamox
Page 17 and 18: Cancer Pharmacogenomics • Introdu
Page 19 and 20: Cytidine Analogues Ara-C N NH 2 Gem
Page 21 and 22: Gemcitabine-AraC IC50 - Expression
Page 23 and 24: The Therapeutic Revolution Goodman
Page 25 and 26: FKBP5 Functional Characterizatoin C
Page 27 and 28: Pharmacogenomics Genomic Era Develo
Page 29 and 30: Cancer Pharmacogenomics Challenges
Page 32: Mayo Pharmacogenomics Laboratories

Cancer Pharmacogenomics Development, Science, Translation

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?